Editorial: Chemoresistance and immunotherapy in solid tumors

Editorial: Autophagy in solid tumors and inflammation: mechanisms and therapies
Zhenyi An, Safa Larafa, Silvia Vega Rubin de Celis
Frontiers in Oncology20 Oct 2026Peer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossref
Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy
S. Wang, Q. Xu, M. Wu +5
bioRxiv26 Sep 2026PreprintAll rights reservedFull textOncologybioRxiv
1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
Justin Moser, Igor Puzanov, Hans Hammers +15
Journal for ImmunoTherapy of Cancer8 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
CAR-NK cell immunotherapy: a comprehensive review of engineering platforms, clinical applications in hematological and solid tumors.
Salma Mohamed Awadallah, NourEldin Elmesalamy, Ahmed Reda Bahr +3
Journal of cancer research and clinical oncology23 Oct 2026Peer-reviewedCC BYFull textOncologyEurope PMCDOAJ
53L10 T-cell engager tribody for immunotherapy of multiple solid tumors
Margherita Passariello, Martina Belardo, Toshikazu Inoue +4
Frontiers in Immunology6 Oct 2026Peer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC

Cite

BibTeX

@article{xu2026editorial,
  title = {{Editorial: Chemoresistance and immunotherapy in solid tumors}},
  author = {Junchao Xu},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.2013215},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2013215/full},
  note = {CC BY 4.0},
}

RIS

TY  - JOUR
TI  - Editorial: Chemoresistance and immunotherapy in solid tumors
AU  - Junchao Xu
PY  - 2026
DA  - 2026/10/15
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.2013215
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2013215/full
SN  - 1664-3224
ER  -

Related

Cite